

# UC San Diego

## UC San Diego Previously Published Works

### Title

Inactivating mutations in GNA13 and RHOA in Burkitt's lymphoma and diffuse large B-cell lymphoma: a tumor suppressor function for the G $\alpha$ 13/RhoA axis in B cells

### Permalink

<https://escholarship.org/uc/item/77p703t3>

### Journal

Oncogene, 35(29)

### ISSN

0950-9232

### Authors

O'Hayre, M  
Inoue, A  
Kufareva, I  
[et al.](#)

### Publication Date

2016-07-21

### DOI

10.1038/onc.2015.442

Peer reviewed



Published in final edited form as:

*Oncogene*. 2016 July 21; 35(29): 3771–3780. doi:10.1038/onc.2015.442.

## Inactivating Mutations in *GNA13* and *RHOA* in Burkitt's Lymphoma and Diffuse Large B cell Lymphoma: A Tumor Suppressor Function for the $G\alpha_{13}$ /RhoA Axis in B Cells

Morgan O'Hayre<sup>1</sup>, Asuka Inoue<sup>2,3</sup>, Irina Kufareva<sup>4</sup>, Zhiyong Wang<sup>1</sup>, Constantinos M. Mikelis<sup>5</sup>, Rebecca A. Drummond<sup>6</sup>, Silvia Avino<sup>1,7</sup>, Kira Finkel<sup>1</sup>, Khalid Kalim<sup>8</sup>, Giovanni DiPasquale<sup>9</sup>, Fukun Guo<sup>8</sup>, Junken Aoki<sup>2</sup>, Yi Zheng<sup>8</sup>, Michail S. Lionakis<sup>6</sup>, Alfredo A. Molinolo<sup>1</sup>, and J. Silvio Gutkind<sup>1,\*</sup>

<sup>1</sup>Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20852, USA

<sup>2</sup>Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Miyagi 980-8578, Japan

<sup>3</sup>PRESTO, Japan Science and Technology Agency (JST), Kawaguchi, Saitama 332-0012, Japan

<sup>4</sup>Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California, San Diego, La Jolla, CA 92093, USA

<sup>5</sup>Department of Biomedical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA

<sup>6</sup>Fungal Pathogenesis Unit, Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA

<sup>7</sup>Department of Pharmacy, Health & Nutritional Sciences, University of Calabria, via P Bucci, 87036 Rende (Cs), Italy

<sup>8</sup>Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

<sup>9</sup>Molecular Physiology and Therapeutics Branch, National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD 20852, USA

### Abstract

G-proteins and their cognate G-protein coupled receptors (GPCRs) function as critical signal transduction molecules that regulate cell survival, proliferation, motility and differentiation. The aberrant expression and/or function of these molecules have been linked to the growth, progression and metastasis of various cancers. As such, the analysis of mutations in the genes encoding

---

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:[http://www.nature.com/authors/editorial\\_policies/license.html#terms](http://www.nature.com/authors/editorial_policies/license.html#terms)

\*Corresponding author: Current address, UC San Diego Moores Cancer Center 3855 Health Sciences Drive, #0803, La Jolla, CA 92093.

### Conflict of Interest

Authors have no conflicts of interest to declare.

GPCRs, G-proteins and their downstream targets provides important clues regarding how these signaling cascades contribute to malignancy. Recent genome-wide sequencing efforts have unveiled the presence of frequent mutations in *GNAI3*, the gene encoding the G-protein  $G\alpha_{13}$ , in Burkitt's lymphoma and Diffuse Large B cell lymphoma (DLBCL). We found that mutations in the downstream target of  $G\alpha_{13}$ , RhoA, are also present in Burkitt's lymphoma and DLBCL. By multiple complementary approaches, we now show that these cancer-specific *GNAI3* and *RHOA* mutations are inhibitory in nature, and that the expression of wild type  $G\alpha_{13}$  in B cell lymphoma cells with mutant *GNAI3* has limited impact *in vitro* but results in a remarkable growth inhibition *in vivo*. Thus, although  $G\alpha_{13}$  and RhoA activity has previously been linked to cellular transformation and metastatic potential of epithelial cancers, our findings support a tumor suppressive role for  $G\alpha_{13}$  and RhoA in Burkitt's lymphoma and DLBCL.

## Keywords

G-protein; GPCR; RhoA; tumor suppressor; B cell lymphoma

---

## Introduction

G-protein coupled receptors (GPCRs) represent the largest class of cell surface receptors and when activated by extracellular ligands, they transmit signals involved in cell growth, proliferation, survival, differentiation and motility (1). GPCRs initiate signal transduction cascades by coupling to and activating heterotrimeric G-proteins. Depending on the coupling specificity, a given GPCR may couple to one or more different  $G\alpha$  proteins, which are grouped into four main families:  $G\alpha_{12}$  (including  $G\alpha_{13}$ ),  $G\alpha_s$ ,  $G\alpha_i$ , and  $G\alpha_q$  (including  $G\alpha_{11}$ ). Each family of G-proteins activates distinct sets of second messenger and kinase signaling cascades (1).

Heterotrimeric G-proteins are major cellular signaling hubs, and they are activated upon binding to GPCRs or non-receptor guanine nucleotide exchange factors (GEFs) (2). Due to their important roles in regulating cell survival, proliferation and movement, it is not surprising that tumors often harbor mutations in or exhibit aberrant expression of G-proteins and their GEFs (3). For example, activating mutations in *GNAI1* and *GNAQ*, encoding  $G\alpha_{11}$  and  $G\alpha_q$  respectively, were recently discovered to be the key oncogenic drivers in uveal melanoma (4–6).  $G\alpha_s$  is the most frequently mutated G-protein in human cancers and activating mutations in the gene, *GNAS*, have been found in a variety of neoplasms including pituitary, thyroid, pancreatic, biliary tract, colon and small intestine and a variety of other tumors (3). Furthermore, constitutively active mutants of genes encoding  $G\alpha_i$ ,  $G\alpha_o$ ,  $G\alpha_q$ ,  $G\alpha_{12}$ , and  $G\alpha_{13}$  were found to induce cellular transformation in experimental systems (reviewed in (1, 7)).

Despite the transforming capacity of constitutive  $G\alpha_{12}$  and  $G\alpha_{13}$  activity in experimental systems and numerous implications of this G-protein family and downstream targets in cancer metastasis (8–13), activating mutations in the *GNAI3* and *GNAI2* genes in patient tumor samples have not been described. However, recent large-scale sequencing efforts have revealed the presence of *GNAI3* mutations in Burkitt's lymphoma and Diffuse Large B cell

Lymphoma (DLBCL) (14, 15). Interestingly, recent studies in mouse models demonstrated that conditional B cell deficiency in  $G\alpha_{13}$  or the  $G\alpha_{13}$ -coupled sphingosine 1 phosphate receptor 2 (S1P2) result in DLBCL-like phenotypes (16, 17). Based on the analysis of deposited sequencing data from tumors in the Catalog of Somatic Mutations in Cancer (COSMIC), mutations in *GNA13* in human Burkitt's lymphoma and DLBCL are highly statistically significant over background cancer mutation rate, with p-value and q-value scores of 0 (3), suggesting these mutations are likely not random. However, unlike the activating GTPase domain mutations found in other G-proteins in cancers, including  $G\alpha_q$  and  $G\alpha_s$ , the mutations in *GNA13* are distributed throughout the gene. Furthermore, we identified additional mutations in the gene of the major downstream effector of  $G\alpha_{13}$  signaling, RhoA.

In this study, we characterize the mutations identified in *GNA13* and *RHOA* in Burkitt's lymphoma and DLBCL tumor samples to determine how these mutations affect protein function and signaling capacity. We also evaluated the effects of mutations and wild type (WT)  $G\alpha_{13}$  expression on tumor growth and progression in xenograft models. Overall, our results support a tumor suppressive role for the  $G\alpha_{13}$ /RhoA axis in Burkitt's lymphoma and DLBCL. Our data also extend recent findings supporting the presence of disruptive *RHOA* mutations in peripheral T cell lymphomas, suggesting that disruption of RhoA function may have a broad impact in multiple haematological malignancies (18–22).

## Results

### Mutations in *GNA13* and *RHOA* are frequent in Burkitt's Lymphoma and DLBCL tumors

Data from genome-wide sequencing analyses collected through the Catalog of Somatic Mutations in Cancer (COSMIC v72) database reveal the presence of *GNA13* mutations in nearly 2% of all haematopoietic and lymphoid malignancies (Figure 1A). Previous statistical analyses of these mutations indicated p-value and q-value (for false discovery rate) scores approaching 0, suggesting they are unlikely to be random, but rather could have important driver mutation functions (3). Of the haematopoietic and lymphoid malignancies evaluated in COSMIC, most of the *GNA13* mutations are present in B cell lymphomas, primarily Diffuse Large B cell lymphoma (DLBCL) and Burkitt's Lymphoma, for which mutations are harbored in approximately 10% of patient tumor samples (Figure 1A). Mutations in *GNA13* found in Burkitt's lymphoma and DLBCL appeared likely to result in loss of function because nearly 22% (5/23) of the DLBCL mutations (17% of overall in both lymphomas) were nonsense, resulting in a premature STOP codon and all other mutations were non-synonymous (Figure 1A). When mapped onto the crystal structure of *GNA13*, the mutations clustered into multiple regions including the binding interface for the  $G\beta/\gamma$  subunits, the helical domain, conformational switches 1 and 2 (important for nucleotide binding as well as interaction with regulators and effectors), conformational switch 3, the GPCR interface, and directly in the nucleotide pocket (Figures 1A, Supplemental Table 1). An interesting in-frame deletion was observed in the loop connecting the GTPase and the helical domain that can dramatically impair the relative mobility of the two domains. Mutations are therefore not localized into one region and so they could exert a broad influence on the protein function or stability.

RhoA is the main downstream effector of  $G\alpha_{13}$  signaling (23–25), therefore we searched the COSMIC database to determine if there were mutations in *RHOA* in Burkitt's Lymphoma and DLBCL tumors as well. Although less frequent than the *GNA13* mutations, non-redundant *RHOA* mutations were observed in nearly 6% of Burkitt's Lymphoma and almost 1% of DLBCL tumors (Figure 1B), as these *RHOA* mutations were present in separate tumor samples from those with *GNA13* mutations. Taken together, the  $G\alpha_{13}$ /RhoA axis is disrupted in more than 10% of these B cell lymphomas. Interestingly, there was a recurrent R5Q mutation, observed in 7/16 *RHOA* mutations identified in these tumors. Structural analysis of RhoA suggests that R5 is important for GEF binding. Several of the other mutations in *RHOA* also localized to GEF binding residues, indicating that these mutations could influence RhoA activation due to changes in RhoA-GEF interactions (Figure 1B, Supplemental Table 2).

### Characterization of *GNA13* mutations indicates loss of function

In order to determine the consequences of the *GNA13* mutations on  $G\alpha_{13}$  protein function, we prepared and characterized 9 of the mutations from the COSMIC data repository, representing a variety of the structural and functional domains. Plasmids encoding empty vector,  $G\alpha_{13}$  WT,  $G\alpha_{13}$  mutants based on Burkitt's lymphoma and DLBCL tumor samples and an established constitutively active Q226L mutant were transfected into HEK293 cells and  $G\alpha_{13}$  protein expression was assessed by western blot (Figure 2A). Although most of the  $G\alpha_{13}$  mutants were expressed at similar levels to WT, there were a few including L197Q and F245S that had reduced protein expression. Because the  $G\alpha_{13}$  antibody recognizes an epitope in the C-terminus of  $G\alpha_{13}$ , disrupted antibody recognition is unlikely to fully explain the relatively low protein expression observed in the L197Q and F245S mutants. Rather, it could be that these mutants affect protein stability, thus reducing expression.

To evaluate the functional consequences of these mutants, we tested their activity in a serum response factor response element (SRF-RE) luciferase assay, which is used to selectively monitor gene transcription downstream of  $G\alpha_{13}$ -RhoA signaling. The SRF-RE luciferase assay demonstrated that all 9  $G\alpha_{13}$  mutants had significantly reduced basal transcriptional activity relative to WT and constitutively active (Q226L)  $G\alpha_{13}$  (Figure 2B). Due to promiscuity of most  $G\alpha_{13}$ -coupled GPCRs, which often also couple to other G proteins and/or have ligands that target other GPCRs, a synthetic biology approach was employed to determine the effects of the  $G\alpha_{13}$  mutants on ligand-activated  $G\alpha_{13}$  signaling events. The synthetic GPCR (SyR), also known as DREADD (26), is activated by an otherwise biologically inert ligand, clozapine N-oxide (CNO). Because no  $G\alpha_{13}$ -SyR is currently available, an SyR that couples to  $G\alpha_i$  was used in combination with a chimeric G-protein that has  $G\alpha_i$ -coupling specificity (based on the last 5 amino acids at the C-terminus) but retains  $G\alpha_{13}$  signaling response. Additionally, in order to ensure that the responses observed were due to  $G\alpha_{13}$  activity and not influenced by potential  $G\alpha_i$  signaling, a C-I mutation was made in the last 5 amino acids of the  $G\alpha_{13-15}$  chimeras to make them pertussis toxin (PTX)-insensitive and the assay was performed in the presence of PTX. The SRF-RE assay demonstrated that some of the  $G\alpha_{13}$  mutants were completely dead whereas others still retained some ligand-activated response (Figure 2C). Nevertheless, overall SRF-RE activity was lower in all the mutants compared with WT (and basal activity was again lower in all

the mutants). A recently developed TGF- $\alpha$  shedding assay was used as another measurement of  $G\alpha_{13}$  activity (27).  $G\alpha_{13}$  and  $G\alpha_q$  activity are known to induce the shedding of tethered TGF- $\alpha$ , and so we could monitor the release of AP-TGF- $\alpha$  into media as a measurement of  $G\alpha_{13}$  signaling (Figure 3A). Similar to the SRF-RE results, the spontaneous (or basal) activities of all the  $G\alpha_{13}$  mutants were significantly lower than WT or the Q226L constitutively active mutant (Figure 3B, Supplemental Table 3), whereas a few of the mutants still retained some ligand-induced signaling response as determined using the synthetic receptor system, SyR-Gi with the  $G\alpha_{13-15}$  chimeras, (Figure 3C, Supplemental Table 3) and using another receptor that couples to  $G\alpha_{13}$ , the dopamine D2 receptor (Supplemental Figure 1, Supplemental Table 3).

### **GNA13 and RHOA mutations impair RhoA activity**

RhoA is the main downstream effector of  $G\alpha_{13}$  signaling, thus we sought to analyze the effects of the *GNA13* mutations on RhoA activity and to determine the effect of the recurrent RhoA R5Q mutation. We monitored active GTP-bound RhoA using a pull-down assay for three of the  $G\alpha_{13}$  mutants and controls. In line with the previous experiments, the  $G\alpha_{13}$  mutants had considerably reduced levels of active RhoA compared to WT  $G\alpha_{13}$ , constitutively active  $G\alpha_{13}$  Q226L and the thrombin-stimulated positive control (Figure 4A). Next, we evaluated the activity of the R5Q RhoA mutant that had been identified in several DLBCL and Burkitt's lymphoma tumors. The R5Q mutant exhibited reduced activity compared with WT RhoA and the constitutively active Q63L RhoA mutant in both an active RhoA pull down assay (Figure 4B) and an SRF-RE luciferase assay (Figure 4C). However, the RhoA R5Q mutant appeared to retain a little activity compared with the dominant negative T19N RhoA mutant (Figure 4C). Formation of actin stress fibers is often used as another indication of RhoA activity, so we performed a stress fiber formation assay using LifeActin-GFP in MDCK cells. Consistent with the SRF and RhoA pull down results, we observed significant actin stress fiber formation in WT and Q63L constitutively active RhoA-transfected MDCK cells, but not with the R5Q mutant or the dominant negative T19N mutant (Figure 4D). Overall, these data indicate that the *GNA13* and *RHOA* mutations observed in DLBCL and Burkitt's lymphoma tumors result in loss of function of RhoA activity and downstream signaling events.

### **Restoration of $G\alpha_{13}$ WT suppresses tumor growth**

The COSMIC sequencing data indicated the presence of a *GNA13* mutation at L184R in the frequently used Raji Burkitt's lymphoma cell line. Therefore, in order to determine if mutation and thus loss of  $G\alpha_{13}$  activity provides the cells with a growth or survival advantage, we expressed  $G\alpha_{13}$  WT in the cells. First we verified the COSMIC sequencing data in the Raji cell line and confirmed the presence of a heterozygous L184R mutation (Figure 5A). Then, we transduced Raji cells using MSCV puro IRES GFP retrovirus with  $G\alpha_{13}$  WT or vector control. After cell sorting, we were able to achieve a highly GFP-enriched population of cells and verified the expression of  $G\alpha_{13}$  (Figure 5B). B cell lines are notorious for their difficulties in terms of feasibility of genetic manipulations, which prevented us from deploying similar or complementary strategies to express  $G\alpha_{13}$  WT in additional relevant cellular systems. Regarding  $G\alpha_{13}$  function, it was previously reported that  $G\alpha_{13}$  activity has suppressive effects on Akt phosphorylation (17). Thus, we measured

basal Akt phosphorylation at S473 and found that  $G\alpha_{13}$  WT expression in the Raji cells reduced phosphorylated Akt (Figure 5C). Using *in vitro* viability and proliferation assays, we did not observe any differences between the control and  $G\alpha_{13}$  WT-expressing Raji cells (data not shown). In a methocellulose clonogenic assay, WT  $G\alpha_{13}$ -expressing cells showed only a slight reduction in the number of colonies; however, the difference in cell morphology was striking (Figures 5D–E). While the majority of the control Raji cells formed spheroid colonies in the methocellulose, the Raji cells expressing  $G\alpha_{13}$  WT tended to exhibit a more flattened morphology (Figure 5E). Next we tested the Raji control cells and Raji  $G\alpha_{13}$  WT-transduced cells in a tumor xenograft model using NSG (NOD SCID gamma) mice. In line with the role of a tumor suppressor, the restoration of  $G\alpha_{13}$  WT to the Raji cells resulted in significantly delayed and impaired tumor growth and smaller tumor masses and volumes (Figures 5F–H). Histological evaluation of the cells indicated that the Raji cells with  $G\alpha_{13}$  WT expressed were considerably smaller and more necrotic than the control Raji cells (Figures 5I–J). Additionally, the Raji cells expressing  $G\alpha_{13}$  WT were significantly less proliferative, based on Ki67 staining and analysis of tumor sections (Figure 5K). These data indicate that restoration and/or overexpression of  $G\alpha_{13}$  WT influences the survival and/or proliferation of the Raji cells within the tumor microenvironment, which may be the mechanism by which it suppresses tumor growth *in vivo*.

## Discussion

Burkitt's lymphoma and DLBCL are aggressive and prevalent B cell malignancies (28). Although some genetic alterations have been identified and associated with malignancy of these B cell lymphomas, much is still unknown about the majority of the genetic mutations and how these alterations may affect the development and progression of disease (14, 29). Previous genome wide sequencing studies unveiled frequent mutations in *GNAI3*, the gene encoding the G-protein,  $G\alpha_{13}$  (14, 15), and these mutations were found to be highly statistically significant over background cancer mutation rates (3). Although activity of  $G\alpha_{13}$  has previously been linked to cellular transformation in fibroblasts as well as tumor cell invasion in several cancers including breast cancer and prostate cancer (7, 30–32), our characterization of the *GNAI3* mutations present in human Burkitt's lymphoma and DLBCL tumors indicates that these mutations rather result in loss of function and/or reduced protein stability. Furthermore, we demonstrated that expression of wild-type  $G\alpha_{13}$  to Burkitt's lymphoma cells with mutated *GNAI3* results in reduced tumor growth in xenograft models and altered cell morphology and growth in a methocellulose colony assay.

Recent elegant genetic mouse models support our loss-of-function characterization of *GNAI3* mutations present in DLBCL and Burkitt's lymphoma, as mice deficient in lymphoid lineage for  $G\alpha_{13}$  or the  $G\alpha_{13}$ -coupled receptor, sphingosine 1 phosphate receptor 2 (S1P2), exhibited an increase in total T cell and B cell numbers and resulted in an outgrowth of cells classified as diffuse large B cell lymphoma (16, 17, 33). Specifically, these studies identified a migration defect and an increase in phosphorylated Akt in germinal center (GC) B cells caused by S1P2 or  $G\alpha_{12}/G\alpha_{13}$  deficiency. Thus, signaling through the  $G\alpha_{12}/G\alpha_{13}$  axis via GPCRs, including S1P2 and the recently characterized P2Ry8, is proposed to help confine B cells to the GC and limit B cell expansion (17). Loss of this axis would therefore allow cells to escape the GC and populate lymph nodes as is characteristic

of diffuse large B cell lymphomas. However, in addition to the migration defects observed in these previous studies, our data indicate a direct role for  $G\alpha_{13}$  in growth suppression of B cells *in vivo* and suggest  $G\alpha_{13}$  may influence their survival, and/or differentiation state.

Previous sequencing of non-Hodgkin's lymphomas reported frequent *GNAI3* mutations that were enriched in germinal center B cell (GCB) type DLBCL (34). Of interest, DLBCL have been recently classified in multiple distinct groups based on their histological and biological characteristics and morphological features (35). Thus, based on our findings it is possible that DLBCL harboring *RHOA* or *GNAI3* mutations may exhibit particular characteristics. Indeed, further characterization of *RHOA* and *GNAI3* mutations in relation to subgroup, stage and patient survival is warranted once more information becomes available.

To evaluate the mechanisms by which the *GNAI3* mutations may alter signaling that could affect the growth and morphology of the B cells, we first investigated possible effects on the major downstream effector, RhoA. The constitutive/basal activity of RhoA was found to be significantly reduced in all 9 of the  $G\alpha_{13}$  mutants tested compared with WT  $G\alpha_{13}$ . Although a few of the mutants still had some ligand-induced signaling responses, the overall levels of activity were reduced compared with WT. Furthermore, these ligand-induced signaling assays were performed with receptor overexpression systems, so it is possible that these ligand-responses may not be as pronounced in more physiological systems.

Because the  $G\alpha_{13}$  mutants critically impacted RhoA activity, we investigated whether independent mutations in *RHOA* were present in DLBCL and Burkitt's lymphoma tumors by searching the COSMIC database. Indeed, mutations in *RHOA* were identified in several patient tumors that were independent from those with *GNAI3* mutations. Intriguingly, a recurrent glutamine substitution at R5 of RhoA was observed in several patient tumors, aligned with the recent description of *RHOA* mutations, including a recurrent R5Q mutation, in 8.5% of pediatric Burkitt's Lymphoma cases studied (36). Correlating with the loss of function data observed with the  $G\alpha_{13}$  mutations, our data indicate that the activity of R5Q is significantly impaired compared with WT RhoA in active RhoA pull down, SRF-RE luciferase and actin stress fiber formation assays. Based on structural modeling and known interactions, R5 appears to be directly involved in the interaction with RhoGEFs (particularly RhoGEFs 11, 12, and DBS). Although no mutations were found in the RhoGEFs most frequently activated by  $G\alpha_{13}$ , p115 (ARHGEF1), LARG (ARHGEF12), or PDZ RhoGEF (ARHGEF11), this is not surprising due to the redundancy of the RhoGEFs and the opportunities for compensation (37, 38). Interestingly, inactivating or dominant negative mutations in RhoA were recently identified in 50–70% of peripheral T cell lymphomas (18–22), suggesting that the  $G\alpha_{13}$ /RhoA pathway may have tumor suppressive functions in other haematological malignancies as well.

Although  $G\alpha_{13}$  and RhoA have been associated with cellular transformation and characterized as growth promoting in fibroblasts and some epithelial cancer models, this axis appears to have the opposite effect in B cell lymphomas. This sort of duality in function based on cellular context is not unheard of and has been observed with other key pathways, including JNK and transforming growth factor beta signaling pathways (39, 40). Although the precise mechanism by which  $G\alpha_{13}$ /RhoA axis may inhibit cell growth in B cells requires



further exploration, the reduction in phosphorylated Akt (Ser473) associated with  $G\alpha_{13}$  activity could in part affect the growth and survival of B cells (16, 17). Additionally, we observed distinct morphological changes in the cells with mutant  $G\alpha_{13}$  compared with WT- $G\alpha_{13}$  both in the methocellulose clonogenic assay and in the histology analysis from tumor xenografts, suggesting other factors may play a role. Nevertheless, the reasons why  $G\alpha_{13}$  and RhoA may exhibit pro-tumorigenic effects in some cancers while having tumor suppressive functions in other cancers requires further investigation. In this regard, once better tools become available for manipulation of B cells and B cell lines, it will be possible to determine how disruption of *GNA13* or *RHOA* in normal human B cells and other Burkitt's lymphoma and DLBCL lines influences their growth and morphology, thereby helping to elucidate fully the repertoire of tumor suppressive signals induced by  $G\alpha_{13}$ /RhoA in B cells.

Characterization of tumor mutations provides valuable information for how to precisely identify causes of disease and best treatment options. Our data suggest that the mutations identified in the  $G\alpha_{13}$  signaling pathway in Burkitt's lymphoma and DLBCL tumors result in loss of function, and that restoration and/or activation of this signaling pathway may help reduce tumor growth and progression. Overall, the characterization of these mutations may enable more precise treatment in the >10% of patients with mutations in *GNA13* and *RHOA* in DLBCL and Burkitt's lymphoma.

## Materials and Methods

### Identification of interaction interfaces for mapping and structural characterization of mutations

Structures of RhoA protein and its complexes were retrieved from the PDB. Per-residue contact strengths of RhoA with each of the available co-crystallized binding partners were measured as described in (41, 42) for residue side-chains only and averaged over multiple structures of homologous complexes. Based on this analysis, residues were classified as a part of GAP interface, GEF interface, or nucleotide binding pocket. Conformational switches I and II were found to be extensively involved in binding of both GAPs and GEFs. The analysis for  $G\alpha_{13}$  was conducted similarly; however, because there are no structures of trimeric  $\alpha/\beta/\gamma$  complexes for  $G\alpha_{13}$  and because the N-terminal helix is absent from all available structures, this part of the protein was modeled and  $G\beta/\gamma$  interface was mapped by homology with bovine Gat (transducin, PDB 1got), rat  $G\alpha_{i1}$  (PDB 1gp2), and mouse  $G\alpha_q$  (PDB 3ah8).

### DNA constructs and site directed mutagenesis

MSCV puro IRES GFP (PIG) and pBABE puro retroviral vectors were obtained from Addgene (43, 44). The SyR-Gi plasmid (also known as Gi-DREADD) was originally provided by Dr. Bryan Roth and was subcloned into the pBABE retroviral vector.  $G\alpha_{13}$  and N-terminally tagged AU5-RhoA were cloned into our in house pCEFL vector and mutations as indicated were prepared by site directed mutagenesis using the QuikChange Lightning Kit (Agilent, Santa Clara, CA).  $G\alpha_{13-15}$  chimeras were prepared by PCR substitution of the last 5 amino acids of  $G\alpha_{13}$  with the  $G\alpha_{i1}$  sequence including a C-I mutation to make the

plasmid pertussis toxin insensitive (the last 5 amino acids were as follows: DIGLF). Sequences were confirmed by DNA sequence analysis (NIDCR shared resource facility). A plasmid for alkaline phosphatase-fused transforming growth factor- $\alpha$  (AP-TGF $\alpha$ ) (45) was kindly provided by Prof. Shigeki Higashiyama, Ehime University, Japan. A human dopamine D2 receptor (D2R, long isoform) was inserted into the pCAGGS expression plasmid as previously described (27).

### Genomic DNA isolation and sequencing

Raji cells were obtained from ATCC (ATCC CCL-86). Genomic DNA was isolated from  $5 \times 10^6$  Raji cells using the QiaAmp DNA isolation kit (Qiagen) and PCR was performed on the genomic DNA in the region surrounding the 184 amino acid position using AccuPrime Pfx Supermix (Life Technologies, Grand Island, NY). PCR primer details are included in supplemental information.

### Retrovirus production and infection

Retrovirus from MSCV PIG empty vector and expressing  $G\alpha_{13}$  WT was produced by transfection of HEK293t/17 cells in a poly-lysine coated 6-well plate with 1  $\mu$ g of MSCV plasmid DNA, 0.67  $\mu$ g of gag/pol and 0.33  $\mu$ g of VSV-G using Turbofect transfection reagent (Life Technologies). Virus for pBABE SyR-Gi was similarly prepared by transfecting 1  $\mu$ g of pBABE SyR-Gi, 0.67  $\mu$ g of gag/pol and 0.33  $\mu$ g of VSV-G. Viral supernatants were collected at 48 h and 72 h post-transfection and filtered with 0.45  $\mu$ m PVDF-filters onto target cells. For HEK293 cells transduced with pBABE SyR-Gi, 6  $\mu$ g/ml of polybrene was added with the viral supernatants; cells were then selected with 1  $\mu$ g/ml puromycin (Life Technologies) to generate a stable line. For transduction of Raji cells with MSCV virus, Raji cells were seeded onto retronectin-coated plates (Takara, Madison, WI) and centrifuged with viral supernatants at 2000 rpm for 2 hr and then incubated overnight at 37°C/5% CO<sub>2</sub>. MSCV-transduced Raji cells were allowed to recover before FACS sorting for GFP expression using a BD FACSAria III Cell Sorter (NIDCR Shared Resource Facility). Raji cells were cultured in RPMI media (Sigma, St. Louis, MO) supplemented with 10% FBS.

### SRF-RE luciferase assay

A serum response factor response element (SRF-RE) luciferase assay was performed by seeding HEK293 cells in a poly-lysine coated 24-well plate and culturing in DMEM supplemented with 10% FBS for 24 h. Cells were then co-transfected with 100 ng  $G\alpha_{13}$  plasmid DNA or control, 50 ng pSRF-RE-firefly luciferase reporter DNA, and 20 ng pRL-renilla luciferase using lipofectamine 2000 (Life Technologies) transfection reagent. For stimulated SRF response, HEK293 cells stably transduced with SyR-Gi were similarly transfected. The day after transfection, cells were serum starved overnight in the presence of 50 ng/ml pertussis toxin (List Biological Laboratories, Campbell, CA) and then stimulated for 6 h with CNO prior to harvesting the cells. For all SRF-luciferase assays, cells were lysed and luciferase activity was determined using Dual-Glo Luciferase Assay Kit (Promega, Madison, WI). Chemiluminescence was measured using a BioTek Synergy Neo plate reader and the SRF-RE activation was calculated as the ratio of firefly to renilla

luciferase levels. The assays were performed three times in duplicates and results are presented as the mean  $\pm$  standard deviation.

### Rho-GTP pull down assay and western blot

Antibodies to RhoA (catalog # 2117), pAkt (Ser473) (catalog #4060), Akt (catalog #9272), and  $\alpha$ -tubulin (catalog #3873) were obtained from Cell Signaling Technology. G $\alpha_{13}$  antibody was obtained from Santa Cruz (catalog # sc-26788). Cells for western blot lysates were lysed on ice in RIPA buffer (Sigma) containing protease and phosphatase inhibitors (Thermo Scientific, Pittsburgh PA) and clarified by centrifugation at 13,000 rpm for 10 min at 4°C. The relative G $\alpha_{13}$  protein expression levels were quantified by densitometry using ImageJ and normalized to  $\alpha$ -tubulin; data represents an average of three independent western blots (mean  $\pm$  standard deviation). GST-tagged Rhotekin RBD beads were purchased from Millipore for pull down assays to detect active RhoA. HEK293 cells were seeded in 6 cm plates and transfected with lipofectamine 2000 for 48 h with 4  $\mu$ g of plasmid DNAs. Cells were serum starved overnight and harvested for pull downs with 350  $\mu$ l of recommended lysis buffer. Lysates were clarified and 50  $\mu$ l of lysate was saved for input and the remaining lysate was rotated in tubes with the GST-tagged Rhotekin RBD beads. A three minute thrombin (Sigma) stimulation (1 U/mL) was used as a positive control. Lysates were resolved on SDS-PAGE gels, transferred onto PVDF membranes (Millipore, Billerica, MA), probed with appropriate antibodies and developed with ECL and film (GE healthcare, Piscataway, NJ) or scanned on an Odyssey imager.

### Tumor xenograft model and Tissue Analysis

Ten-week old female NOD-*scid* IL2R $\gamma$ <sup>null</sup> (NOD.Cg-*Prkdc*<sup>scid</sup> *Il2rg*<sup>tm1Wjl</sup>/SzJ) mice were obtained from the Jackson Laboratory and randomly assigned for injection with tumor cells. Raji cells transduced with MSCV PIG control or MSCV PIG G $\alpha_{13}$  WT were resuspended in phosphate buffered saline (PBS) and  $5 \times 10^6$  cells in a 200  $\mu$ l volume were injected into the right and left flanks of five mice for each group (ten tumors in total for each group. One injection was excluded from the Raji control group due to an injection error). Tumors were monitored two to three times a week and mice were sacrificed all together once the largest tumors reached approximately 1 cm<sup>3</sup> volume. Tumor measurements were performed by a blinded individual and the measurements were recorded by an un-blinded person. An initial pilot study was performed with 4 tumors in each group, which was used to determine the appropriate sample size. This study was then expanded and repeated two more times; data trends were the same in all three experiments. Necropsies were performed and tumors were weighed, measured and imaged and tumor sections were cut and fixed in z-fix and embedded in paraffin for histology and immunohistochemistry (IHC) analysis as previously described (46) and elaborated in supplemental information. Individual data points are shown in the scatter dot plots to indicate variance in the data and indicates the mean  $\pm$  standard error of the mean. These animal studies were carried out according to National Institutes of Health (NIH) approved protocols (ASP # 13-695) in compliance with the NIH Guide for the Care and Use of Laboratory Mice.

### TGF $\alpha$ shedding assay

TGF $\alpha$  shedding assay was performed as described previously (27) and as detailed in supplemental information. Briefly, HEK293A cells were seeded in 12-well plates and transfected using lipofectamine 2000 (Life Technologies) with a combination of the following plasmids: AP-TGF $\alpha$ -encoding plasmid, a GPCR-encoding plasmid and a G $\alpha$ -encoding plasmid. After 24 h, cells were harvested with a trypsin-EDTA solution, washed with D-PBS, suspended in Hank's balanced salt solution containing 5 mM HEPES (pH 7.4), and seeded in a 96-well plate and incubated for 30 min. The seeded cells were treated with various concentrations of a GPCR ligand (10  $\mu$ l per well) and incubated for 1 h. Conditioned media (CM, 80  $\mu$ l/well) was transferred into a blank 96-well plate. Alkaline phosphatase (AP) solution was added to both the CM plate and the cell plate (80  $\mu$ l/well). Absorbance at 405 nm of the two plates was measured before and after 1 h incubation at room temperature, using a SpectraMax 340PC384 microplate reader (Molecular Devices, Sunnyvale, CA). TGF $\alpha$  shedding data are shown as the mean  $\pm$  standard deviation.

Spontaneous activity of G $\alpha_{13}$  was measured by a previously described method with a slight modification (47). Briefly, HEK293A cells were seeded in 96-well plates in Opti-MEM (80  $\mu$ l/well), transfected with lipofectamine 2000 reagent (0.1  $\mu$ l/well), the AP-TGF $\alpha$ -encoding plasmids (20 ng/well), G $\alpha_{13}$ -encoding plasmid (5 to 20 ng/well) and the pCEFL vector plasmid, which was used to adjust total volume of transfected plasmid. After adding the transfection solution, the cells were incubated for 24 h and then AP-TGF $\alpha$  release was measured as described above.

### Actin stress fiber formation and confocal imaging

Madin-Darby Canine Kidney (MDCK) cells were seeded onto poly-lysine coated glass cover slips (Fisher) in a 6-well plate and transfected with 1  $\mu$ g LifeActin GFP and 1  $\mu$ g of pCEFL RhoA plasmid or vector control using lipofectamine 2000. Cells for immunofluorescence (IF) imaging were washed with PBS and fixed with 2% formaldehyde – PBS solution for 12 min at room temperature. Fixed cells were washed twice with PBS and then mounted onto glass slides (Thermo Scientific/Fisher) with Fluorosave (Millipore/Calbiochem) mounting solution. Confocal images were collected on a Zeiss LSM-700 laser scanning microscope with a 40 $\times$  oil immersion lens using 488 nm excitation for the LifeActin GFP.

### Methocellulose clonogenic assay

Methocult<sup>TM</sup> (H4434) was purchased from Stem Cell Technologies and a clonogenic assay was performed by seeding 2000 Raji cells in 1 mL of Methocult<sup>TM</sup> in triplicate in a 6 well plate. Colonies were allowed to grow for 14 days and then number of colonies per well and morphology of the colonies were analyzed. Results are shown as the mean  $\pm$  standard deviation. Statistics were calculated using GraphPad Prism 6 using a paired t-test.

### Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments


This study was supported by the National Institute of Dental and Craniofacial Research intramural program at NIH. We thank Maria S. Degese for her help with immunohistochemistry. A.I. was funded by PRESTO from JST. J.A. was funded by CREST from JST. We thank Miho Morikawa for technical assistance with the TGF $\alpha$  shedding assay. RAD and MSL are supported by the Division of Intramural Research, NIAID, NIH. IK is supported by NIH grants R01 GM071872 and R01 AI118985.

## References

1. Dorsam RT, Gutkind JS. G-protein-coupled receptors and cancer. *Nature reviews Cancer*. 2007; 7(2):79–94. [PubMed: 17251915]
2. Garcia-Marcos M, Ghosh P, Farquhar MG. GIV/Girdin transmits signals from multiple receptors by triggering trimeric G protein activation. *The Journal of biological chemistry*. 2015; 290(11):6697–704. Epub 2015/01/22. [PubMed: 25605737]
3. O'Hayre M, Vazquez-Prado J, Kufareva I, Stawiski EW, Handel TM, Seshagiri S, et al. The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer. *Nature reviews Cancer*. 2013; 13(6):412–24. Epub 2013/05/04.
4. Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, et al. Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. *Cancer cell*. 2014; 25(6):831–45. Epub 2014/06/03. [PubMed: 24882515]
5. Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. *Nature*. 2009; 457(7229):599–602. Epub 2008/12/17. [PubMed: 19078957]
6. Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, et al. Mutations in GNA11 in uveal melanoma. *N Engl J Med*. 2010; 363(23):2191–9. Epub 2010/11/19. [PubMed: 21083380]
7. Dhanasekaran N, Heasley LE, Johnson GL. G protein-coupled receptor systems involved in cell growth and oncogenesis. *Endocr Rev*. 1995; 16(3):259–70. [PubMed: 7671848]
8. Kelly P, Moeller BJ, Juneja J, Booden MA, Der CJ, Daaka Y, et al. The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. *Proceedings of the National Academy of Sciences of the United States of America*. 2006; 103(21):8173–8. [PubMed: 16705036]
9. Kelly P, Stemmler LN, Madden JF, Fields TA, Daaka Y, Casey PJ. A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion. *The Journal of biological chemistry*. 2006; 281(36):26483–90. [PubMed: 16787920]
10. Gutkind, JS.; Coso, OA.; Xu, N. G12 and G13  $\alpha$  subunits of heterotrimeric G proteins: A novel family of oncogenes. In: MSA, editor. *G Proteins, Receptors, and Disease*. Totowa, NJ: Humana Press; 1998. p. 101-17.
11. Juneja J, Casey PJ. Role of G12 proteins in oncogenesis and metastasis. *British journal of pharmacology*. 2009; 158(1):32–40. Epub 2009/05/09. [PubMed: 19422395]
12. Xu N, Bradley L, Ambdukar I, Gutkind JS. A mutant alpha subunit of G12 potentiates the eicosanoid pathway and is highly oncogenic in NIH 3T3 cells. *Proceedings of the National Academy of Sciences of the United States of America*. 1993; 90(14):6741–5. [PubMed: 8393576]
13. Xu N, Voyno-Yasenetskaya T, Gutkind JS. Potent transforming activity of the G13 alpha subunit defines a novel family of oncogenes. *Biochemical and biophysical research communications*. 1994; 201(2):603–9. [PubMed: 8002992]
14. Love C, Sun Z, Jima D, Li G, Zhang J, Miles R, et al. The genetic landscape of mutations in Burkitt lymphoma. *Nature genetics*. 2012; 44(12):1321–5. Epub 2012/11/13. [PubMed: 23143597]
15. Lohr JG, Stojanov P, Lawrence MS, Auclair D, Chapuy B, Sougnez C, et al. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing. *Proceedings of the National Academy of Sciences of the United States of America*. 2012; 109(10):3879–84. Epub 2012/02/22. [PubMed: 22343534]


16. Green JA, Suzuki K, Cho B, Willison LD, Palmer D, Allen CD, et al. The sphingosine 1-phosphate receptor SIP(2) maintains the homeostasis of germinal center B cells and promotes niche confinement. *Nat Immunol.* 2011; 12(7):672–80. Epub 2011/06/07. [PubMed: 21642988]
17. Muppidi JR, Schmitz R, Green JA, Xiao W, Larsen AB, Braun SE, et al. Loss of signalling via Galpha13 in germinal centre B-cell-derived lymphoma. *Nature.* 2014; 516(7530):254–8. Epub 2014/10/03. [PubMed: 25274307]
18. Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. *Nature genetics.* 2014; 46(4):371–5. Epub 2014/03/04. [PubMed: 24584070]
19. Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. *Nature genetics.* 2014; 46(2):171–5. Epub 2014/01/15. [PubMed: 24413737]
20. Cools J. RHOA mutations in peripheral T cell lymphoma. *Nature genetics.* 2014; 46(4):320–1. Epub 2014/03/29. [PubMed: 24675518]
21. Manso R, Sanchez-Beato M, Monsalvo S, Gomez S, Cereceda L, Llamas P, et al. The RHOA G17V gene mutation occurs frequently in peripheral T-cell lymphoma and is associated with a characteristic molecular signature. *Blood.* 2014; 123(18):2893–4. Epub 2014/05/03. [PubMed: 24786457]
22. Palomero T, Couronne L, Khiabani H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. *Nature genetics.* 2014; 46(2):166–70. Epub 2014/01/15. [PubMed: 24413734]
23. Fromm C, Coso OA, Montaner S, Xu N, Gutkind JS. The small GTP-binding protein Rho links G protein-coupled receptors and Galpha12 to the serum response element and to cellular transformation. *Proceedings of the National Academy of Sciences of the United States of America.* 1997; 94(19):10098–103. [PubMed: 9294169]
24. Hart MJ, Jiang X, Kozasa T, Roscoe W, Singer WD, Gilman AG, et al. Direct Stimulation of the Guanine Nucleotide Exchange Activity of p115 RhoGEF by Galpha13. *Science.* 1998; 280(5372):2112–4. [PubMed: 9641916]
25. Kozasa T, Jiang X, Hart MJ, Sternweis PM, Singer WD, Gilman AG, et al. p115 RhoGEF, a GTPase Activating Protein for Galpha12 and Galpha13. *Science.* 1998; 280(5372):2109–11. [PubMed: 9641915]
26. Armbruster BN, Li X, Pausch MH, Herlitze S, Roth BL. Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand. *Proceedings of the National Academy of Sciences of the United States of America.* 2007; 104(12):5163–8. Epub 2007/03/16. [PubMed: 17360345]
27. Inoue A, Ishiguro J, Kitamura H, Arima N, Okutani M, Shuto A, et al. TGFalpha shedding assay: an accurate and versatile method for detecting GPCR activation. *Nature methods.* 2012; 9(10):1021–9. Epub 2012/09/18. [PubMed: 22983457]
28. Jaffe ES, Pittaluga S. Aggressive B-cell lymphomas: a review of new and old entities in the WHO classification. *Hematology / the Education Program of the American Society of Hematology American Society of Hematology Education Program.* 2011; 2011:506–14. Epub 2011/12/14. [PubMed: 22160082]
29. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. *Nature reviews Clinical oncology.* 2014; 11(1):12–23. Epub 2013/11/13.
30. Rasheed SA, Teo CR, Beillard EJ, Voorhoeve PM, Casey PJ. MicroRNA-182 and microRNA-200a control G-protein subunit alpha-13 (GNA13) expression and cell invasion synergistically in prostate cancer cells. *The Journal of biological chemistry.* 2013; 288(11):7986–95. Epub 2013/01/19. [PubMed: 23329838]
31. Kelly P, Casey PJ, Meigs TE. Biologic functions of the G12 subfamily of heterotrimeric g proteins: growth, migration, and metastasis. *Biochemistry.* 2007; 46(23):6677–87. Epub 2007/05/17. [PubMed: 17503779]
32. Yagi H, Tan W, Dillenburg-Pilla P, Armando S, Amornphimoltham P, Simaan M, et al. A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of

- metastatic breast cancer cells. *Science signaling*. 2011; 4(191):ra60. Epub 2011/09/22. [PubMed: 21934106]
33. Cattoretti G, Mandelbaum J, Lee N, Chaves AH, Mahler AM, Chadburn A, et al. Targeted disruption of the S1P2 sphingosine 1-phosphate receptor gene leads to diffuse large B-cell lymphoma formation. *Cancer research*. 2009; 69(22):8686–92. Epub 2009/11/12. [PubMed: 19903857]
34. Morin RD, Mendez-Lago M, Mungall AJ, Goya R, Mungall KL, Corbett RD, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. *Nature*. 2011; 476(7360):298–303. Epub 2011/07/29. [PubMed: 21796119]
35. Menon MP, Pittaluga S, Jaffe ES. The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification. *Cancer J*. 2012; 18(5):411–20. Epub 2012/09/26. [PubMed: 23006945]
36. Rohde M, Richter J, Schlesner M, Betts MJ, Claviez A, Bonn BR, et al. Recurrent RHOA mutations in pediatric Burkitt lymphoma treated according to the NHL-BFM protocols. *Genes, chromosomes & cancer*. 2014; 53(11):911–6. Epub 2014/07/22. [PubMed: 25044415]
37. Fukuhara S, Chikumi H, Gutkind JS. RGS-containing RhoGEFs: the missing link between transforming G proteins and Rho? *Oncogene*. 2001; 20(13):1661–8. [PubMed: 11313914]
38. Mikelis CM, Palmby TR, Simaan M, Li W, Szabo R, Lyons R, et al. PDZ-RhoGEF and LARG are essential for embryonic development and provide a link between thrombin and LPA receptors and Rho activation. *The Journal of biological chemistry*. 2013; 288(17):12232–43. Epub 2013/03/08. [PubMed: 23467409]
39. Liu J, Lin A. Role of JNK activation in apoptosis: a double-edged sword. *Cell research*. 2005; 15(1):36–42. Epub 2005/02/03. [PubMed: 15686625]
40. Bachman KE, Park BH. Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter. *Current opinion in oncology*. 2005; 17(1):49–54. Epub 2004/12/21. [PubMed: 15608513]
41. Qin L, Kufareva I, Holden LG, Wang C, Zheng Y, Zhao C, et al. Structural biology. Crystal structure of the chemokine receptor CXCR4 in complex with a viral chemokine. *Science*. 2015; 347(6226):1117–22. Epub 2015/01/24. [PubMed: 25612609]
42. Kufareva I, Rueda M, Katritch V, Stevens RC, Abagyan R. Status of GPCR modeling and docking as reflected by community-wide GPCR Dock 2010 assessment. *Structure*. 2011; 19(8):1108–26. Epub 2011/08/11. [PubMed: 21827947]
43. Mayr C, Bartel DP. Widespread shortening of 3'UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. *Cell*. 2009; 138(4):673–84. Epub 2009/08/26. [PubMed: 19703394]
44. Morgenstern JP, Land H. Advanced mammalian gene transfer: high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. *Nucleic acids research*. 1990; 18(12):3587–96. Epub 1990/06/25. [PubMed: 2194165]
45. Tokumaru S, Higashiyama S, Endo T, Nakagawa T, Miyagawa JI, Yamamori K, et al. Ectodomain shedding of epidermal growth factor receptor ligands is required for keratinocyte migration in cutaneous wound healing. *The Journal of cell biology*. 2000; 151(2):209–20. Epub 2000/10/19. [PubMed: 11038170]
46. Wang Z, Martin D, Molinolo AA, Patel V, Iglesias-Bartolome R, Degese MS, et al. mTOR co-targeting in cetuximab resistance in head and neck cancers harboring PIK3CA and RAS mutations. *Journal of the National Cancer Institute*. 2014; 106(9) Epub 2014/08/08.
47. Inoue A, Arima N, Ishiguro J, Prestwich GD, Arai H, Aoki J. LPA-producing enzyme PLA(1)alpha regulates hair follicle development by modulating EGFR signalling. *The EMBO journal*. 2011; 30(20):4248–60. Epub 2011/08/23. [PubMed: 21857648]



**Figure 1.** Sequence and structure localization of mutations in *GNA13* and *RHOA* that are observed in Burkitt's Lymphoma and DLBCL tumors. A) Table of the number and percentage of *GNA13* mutations in haematopoietic malignancies overall and in Burkitt's Lymphoma and DLBCL based on data from COSMIC v72 (top). Linear diagram of mutations along the *GNA13* gene and the functional and structural domains of the protein  $G\alpha_{13}$  (bottom). B) Table of the number and percentage of *RHOA* mutations in haematopoietic malignancies overall and in Burkitt's Lymphoma and DLBCL based on data from COSMIC v72 (top). Linear diagram of mutations along the *RHOA* gene and the functional and structural domains of the protein and the ribbon diagram of RhoA crystal structure (bottom). Structural and functional domains of both proteins are color-coded and indicated on separate lines above the linear diagram and mapped onto the 3D structures. The mutated residue positions are shown as stars on over the corresponding residues of the linear diagrams and as spheres in the 3D structure representation. The nucleotide is shown as yellow skin.



**Figure 2.**

*GNA13* mutations in Burkitt's lymphoma and DLBCL tumor samples result in loss of downstream transcriptional activity based on SRF-RE luciferase assay. A) Representative western blot for Gα<sub>13</sub> expression of cells transfected with Gα<sub>13</sub> WT, mutants based on COSMIC data, constitutively active Q226L mutant, or vector control. Antibody detection of α-tubulin was used as a loading control (top). Densitometry quantification of Gα<sub>13</sub> protein expression of the mutants relative to WT (bottom) as an average of three independent western blots. Error bars indicate standard deviation. B) SRF-RE luciferase assay of spontaneous activity of cells transfected with Gα<sub>13</sub> WT, mutants, constitutively active Q226L mutant, or vector control. Error bars indicate standard deviation. C) SRF-RE luciferase activity of cells expressing SyR-Gi transfected with WT or mutant Gα<sub>13-i5</sub>


chimeras, in the presence (+) and absence (-) of CNO stimulation. Error bars indicate standard deviation.

Author Manuscript


Author Manuscript

Author Manuscript


Author Manuscript



**Figure 3.** *GNA13* mutations in Burkitt's lymphoma and DLBCL tumor samples result in loss of function based on a TGF $\alpha$  shedding assay. A) Schematic representation of the AP-TGF $\alpha$  shedding assay used to monitor activity of the G $\alpha$ <sub>13</sub> mutants. B) AP-TGF $\alpha$  shedding assay for spontaneous/basal activity of G $\alpha$ <sub>13</sub> WT and mutants. Error indicates standard deviation. C) AP-TGF $\alpha$  shedding assay dose response curves of CNO stimulation of cells expressing SyR-Gi transfected with WT or mutant G $\alpha$ <sub>13-i5</sub> chimeras.

**Figure 4.**

Burkitt's lymphoma and DLBCL *GNA13* and *RHOA* mutations impair RhoA activity. A) GST-Rhotekin-RBD pull down assay to monitor RhoA activity in HEK293 cells transfected with vector control (V), WT, constitutively active Q226L or mutant  $G\alpha_{13}$  plasmids. Thrombin (Th) stimulation was used as a positive control. Input lysates were probed for  $G\alpha_{13}$  and for total RhoA and  $\alpha$ -tubulin as loading controls. B) GST-Rhotekin-RBD pull down assay to monitor RhoA activity in HEK293 cells transfected with vector control (V) or RhoA WT, constitutively active Q63L, dominant negative T19N or R5Q mutant plasmids. C) SRF-RE luciferase assay detecting spontaneous activity of cells transfected with vector control, RhoA WT, constitutively active Q63L, dominant negative T19N and the R5Q mutant plasmids. Error bars indicate standard deviation. D) Immunofluorescence images of actin stress fibers in MDCK cells co-transfected with LifeActin-GFP and vector control or RhoA WT, constitutively active Q63L, dominant negative T19N or R5Q mutant plasmids.

**Figure 5.**

$\text{Ga}_{13}$  WT expression has tumor suppressive effects on Raji Burkitt's Lymphoma xenograft tumor growth. A) Sequence chromatogram of Raji cell DNA validating the presence of a heterozygous T→G mutation resulting in the L184R mutation. B) Immunofluorescence imaging for GFP expression of Raji cells transduced with MSCV puro IRES GFP (PIG) vector control or expressing  $\text{Ga}_{13}$  WT. C) Western blot of Raji cells transduced with MSCV puro IRES GFP (PIG) vector control or expressing  $\text{Ga}_{13}$  WT. Lysates were probed for  $\text{Ga}_{13}$  and pAkt S473 expression and for total Akt and  $\alpha$ -tubulin as loading controls. D) Number of colonies formed in a methocellulose clonogenic assay of Raji control and  $\text{Ga}_{13}$  WT-expressing cells. Data represents the averages of three independent experiments performed in duplicate or triplicate. Error indicates standard deviation and a two-tailed t-test was used to determine statistical significance. E) Percentage of colonies exhibiting spheroid, flat or mixed morphologies (representative images on right) in Raji control and  $\text{Ga}_{13}$  WT-expressing cells. F) Tumor volume measurements (error bars represent standard error of the mean (SEM)) of Raji control (n=9) and  $\text{Ga}_{13}$  WT-expressing (G13 WT, n=10) tumor xenografts over time, starting with injections of the tumor cells at Day 0. G) Graphs of the mean (error bars represent SEM) of final tumor masses (left) and final tumor volumes (right) of Raji control and  $\text{Ga}_{13}$  WT (G13 WT) tumors. H) Representative image of Raji control and  $\text{Ga}_{13}$  WT (G13 WT) tumors. A two-tailed t-test was used to determine statistical significance. I) H&E staining of tissue sections from Raji control and  $\text{Ga}_{13}$  WT tumors. H&E shows viable round atypical cells infiltrating skeletal muscle, aberrant mitotic figures (arrowhead) and apoptotic cells (star) in the Raji control image. H&E shows the Raji  $\text{Ga}_{13}$  WT tumor is

highly necrotic with numerous ghost cells, eosinophilic cell bodies lacking nuclear structure (star), and chromatin dust (arrowhead) observed. J) Quantification of necrotic area in Raji control (n=5) and Raji  $G\alpha_{13}$  WT (n=5) tumors analyzed. Statistics were based on a Mann Whitney test. K) Quantification of Ki67 immunohistochemistry staining in Raji control (n=5) and Raji  $G\alpha_{13}$  WT (n=5) tumors. Statistics were based on a t-test.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript